PL2074123T3 - Nowe związki o działaniu przeciwlękowym - Google Patents

Nowe związki o działaniu przeciwlękowym

Info

Publication number
PL2074123T3
PL2074123T3 PL07815371T PL07815371T PL2074123T3 PL 2074123 T3 PL2074123 T3 PL 2074123T3 PL 07815371 T PL07815371 T PL 07815371T PL 07815371 T PL07815371 T PL 07815371T PL 2074123 T3 PL2074123 T3 PL 2074123T3
Authority
PL
Poland
Prior art keywords
anxiolytic compounds
novel anxiolytic
novel
compounds
anxiolytic
Prior art date
Application number
PL07815371T
Other languages
English (en)
Inventor
Jonathan Bayldon Baell
Brad Sleebs
Bernard Luke Flynn
Ian Phillip Street
Nurul Quazi
Chinh Thien Bui
Original Assignee
Bionomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionomics Ltd filed Critical Bionomics Ltd
Publication of PL2074123T3 publication Critical patent/PL2074123T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL07815371T 2006-10-16 2007-10-16 Nowe związki o działaniu przeciwlękowym PL2074123T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85198306P 2006-10-16 2006-10-16
PCT/AU2007/001566 WO2008046135A1 (en) 2006-10-16 2007-10-16 Novel anxiolytic compounds
EP07815371A EP2074123B1 (en) 2006-10-16 2007-10-16 Novel anxiolytic compounds

Publications (1)

Publication Number Publication Date
PL2074123T3 true PL2074123T3 (pl) 2013-04-30

Family

ID=39313499

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07815371T PL2074123T3 (pl) 2006-10-16 2007-10-16 Nowe związki o działaniu przeciwlękowym

Country Status (13)

Country Link
US (7) US8293737B2 (pl)
EP (2) EP2540722B1 (pl)
JP (4) JP5373613B2 (pl)
AU (1) AU2007312936B2 (pl)
CA (2) CA2666219C (pl)
DK (1) DK2074123T3 (pl)
ES (1) ES2399071T3 (pl)
HK (1) HK1132268A1 (pl)
NZ (1) NZ576036A (pl)
PL (1) PL2074123T3 (pl)
PT (1) PT2074123E (pl)
SI (1) SI2074123T1 (pl)
WO (1) WO2008046135A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5373613B2 (ja) 2006-10-16 2013-12-18 バイオノミクス リミテッド 新規な抗不安薬化合物
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
WO2011031745A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
JP2014510065A (ja) 2011-03-02 2014-04-24 バイオノミックス リミテッド 治療薬としての新規な小分子
WO2012116410A1 (en) * 2011-03-02 2012-09-07 Bionomics Limited Methods of treating a disease or condition of the central nervous system
CN103649086A (zh) 2011-05-12 2014-03-19 生态学有限公司 制备萘啶的方法
WO2014036595A1 (en) * 2012-09-04 2014-03-13 Bionomics Limited Compounds and methods for treating diseases or conditions associated with the central nervous system and/or neurite outgrowth
AU2014231722B2 (en) * 2013-03-15 2016-12-22 Bionomics Limited Salts, co-crystals, and polymorphs of an anxiolytic compound
AU2013204159B2 (en) * 2013-03-15 2015-05-07 Bionomics Limited A Crystalline Form of an Anxiolytic Compound
WO2019109150A1 (en) * 2017-12-07 2019-06-13 Bionomics Limited Methods of treating agitation
EP3867252B1 (en) 2018-10-18 2023-12-06 Bionomics Limited 6-indan-2-yloxy-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one derivatives and similar compounds as modulators of the alpha 7 nicotinic acetylcholine receptor for the treatment of anxiety
JP2022548787A (ja) * 2019-09-23 2022-11-21 バイオノミクス リミテッド 治療用製剤およびその使用

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1022214A (en) * 1963-01-31 1966-03-09 Sterling Drug Inc Novel 1,3-disubstituted-1,4-dihydro-4-oxo-1,7-naphthyridines and their preparation
US3506668A (en) * 1965-01-26 1970-04-14 Sterling Drug Inc Method of preparing 8-hydroxy-quinolines
US3429887A (en) 1965-01-26 1969-02-25 Sterling Drug Inc 1,7-naphthyridine-3-carboxylic acid derivatives and their preparation
JPS5023036B1 (pl) 1970-12-29 1975-08-05
JPS5023037B1 (pl) 1970-12-29 1975-08-05
JPS5023037A (pl) * 1973-07-03 1975-03-12
JPS5023036A (pl) * 1973-07-06 1975-03-12
JPS5132594A (en) 1974-09-11 1976-03-19 Kanebo Ltd 1 88 nafuchirijinjudotai no seiho
JPS5331690A (en) * 1976-09-01 1978-03-25 Shionogi & Co Ltd Oxadithiacephalosporins
JPS54163596A (en) 1978-06-09 1979-12-26 Daiichi Seiyaku Co Flonaphlizine derivative
JPS55111486A (en) * 1979-02-19 1980-08-28 Dai Ichi Seiyaku Co Ltd Preparation of pro 3,2,-b -1,8-naphthyridine derivative
JPS55151584A (en) 1979-05-11 1980-11-26 Dai Ichi Seiyaku Co Ltd Preparation of 1,8-naphthyridine derivative
JPS56115787A (en) 1980-02-19 1981-09-11 Dai Ichi Seiyaku Co Ltd Preparation of furo (3,2-b)(1,8)naphthyridine derivative
JPS56118081A (en) 1980-02-22 1981-09-16 Dai Ichi Seiyaku Co Ltd Preparation of 6-methoxy-1,8-naphthyridine
JPS56118083A (en) 1980-02-22 1981-09-16 Dai Ichi Seiyaku Co Ltd Furo(3,2-b)(1,8)naphthyridine derivative
JPS5726688A (en) 1980-07-24 1982-02-12 Dai Ichi Seiyaku Co Ltd Furo 3,2-b 1,8-naphthyridine-7-carboxylic acid derivative
JPS57109790A (en) 1980-12-26 1982-07-08 Dai Ichi Seiyaku Co Ltd Furo(3,2-b)1,8-naphthyridine-7-carboxylic acid derivative
US4404201A (en) * 1981-11-13 1983-09-13 Warner-Lambert Company Cephalosporins
JPS5993080A (ja) 1982-11-18 1984-05-29 Sumitomo Chem Co Ltd １，５−ナフチリジンカルボン酸誘導体
ATE113953T1 (de) 1988-05-10 1994-11-15 Ici Plc Cephalosporine, verfahren zu ihrer herstellung und pharmazeutische präparate.
US5095015A (en) 1990-07-24 1992-03-10 Neurogen Corporation Certain azacycloalkyl imidazopyrimidines; a new class of gaba brain receptor ligands
US5182290A (en) 1991-08-27 1993-01-26 Neurogen Corporation Certain oxazoloquinolinones; a new class of GABA brain receptor ligands
US5182386A (en) 1991-08-27 1993-01-26 Neurogen Corporation Certain imidazoquinoxalinones; a new class of gaba brain receptor ligands
IT1251202B (it) * 1991-09-13 1995-05-04 Mediolanum Farmaceutici Spa 6-amminochinoloni, sintesi ed impiego come antibatterici
US5212310A (en) 1991-12-19 1993-05-18 Neurogen Corporation Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
US5306819A (en) 1992-08-27 1994-04-26 Neurogen Corporation Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands
US5750702A (en) 1993-10-27 1998-05-12 Neurogen Corporation Certain pyrrolo pyridine-3-carboxamides; a new class of GABA brain receptor ligands
US5484944A (en) 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
US5804686A (en) 1996-01-19 1998-09-08 Neurogen Corporation fused pyrrolecarboxamides; a new class of GABA brain receptor ligands
US6211365B1 (en) 1996-01-19 2001-04-03 Neurogen Corporation Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands
US6013650A (en) 1996-03-14 2000-01-11 Neurogen Corporation Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
EP0888300A1 (en) 1996-03-22 1999-01-07 Neurogen Corporation Certain fused pyrrolecarboxamides as gaba brain receptor ligands
US5723462A (en) 1996-04-26 1998-03-03 Neurogen Corporation Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands
PL338783A1 (en) * 1997-08-25 2000-11-20 Neurogen Corp Substituted 4-oxo-naphtyridin-3-carboxamides as ligands of cerebral gaba receptors
US6143760A (en) 1997-08-25 2000-11-07 Neurogen Corporation Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands
AU2793199A (en) 1998-02-26 1999-09-15 Neurogen Corporation 2-(het-)aryl-4-(cyclic amino substituted) heteroaryl fused pyridine derivatives,their preparation and their use as (ant-)agonists for gaba (a) brain receptors
DE19826050A1 (de) 1998-06-12 1999-12-16 Bayer Ag Verfahren zur Herstellung von Chinolon- und Naphthyridoncarbonsäuren und deren Ester
US6177569B1 (en) 1998-08-25 2001-01-23 Neurogen Corporation Oxo-pyridoimidazole-carboxamides: GABA brain receptor ligands
US6414147B1 (en) 1998-12-23 2002-07-02 Neurogen Corporation 2-amino-9-alkylpurines: GABA brain receptor ligands
MXPA01011173A (es) * 1999-05-06 2002-04-24 Neurogen Corp 4-0x0-quinolin-3-carboxamidas sustituidas: ligandos del receptor cerebro de gaba.
US6297256B1 (en) 1999-06-15 2001-10-02 Neurogen Corporation Aryl and heteroaryl substituted pyridino derivatives GABA brain receptor ligands
AU1481701A (en) 1999-11-12 2001-06-06 Neurogen Corporation Bicyclic and tricyclic heteroaromatic compounds
US6723332B2 (en) 2000-05-26 2004-04-20 Neurogen Corporation Oxomidazopyridine-carboxamides
AU2001273639A1 (en) 2000-06-26 2002-01-08 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
US6423956B1 (en) 2000-07-28 2002-07-23 Optical Biopsy Technologies Fiber-coupled, high-speed, integrated, angled-dual-axis confocal scanning microscopes employing vertical cross-section scanning
CA2418853A1 (en) 2000-08-16 2002-02-21 Neurogen Corporation 2,4-substituted pyridine derivatives
EP1315703A1 (en) 2000-09-06 2003-06-04 Neurogen Corporation Aryl substituted tetrahydroindazoles and their use as ligands for the gaba-a receptor
US20020151591A1 (en) 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
AUPR283801A0 (en) 2001-02-01 2001-03-01 Australian National University, The Chemical compounds and methods
BR0207802A (pt) * 2001-03-01 2004-03-09 Pfizer Prod Inc Uso de agonistas inversos de gabaa em combinação com agonistas parciais do receptor de nicotina, estrogênios, moduladores de estrogênio seletivos, ou vitamina e para o tratamento de distúrbios cognitivos
ES2276936T3 (es) 2001-03-27 2007-07-01 Neurogen Corporation (oxo-pirazolo(1,5a)pirimidin-2-il)alquilcarboxamidas.
CA2468159A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 4-aminoquinoline compounds
JP2005519876A (ja) 2001-11-27 2005-07-07 メルク　エンド　カムパニー　インコーポレーテッド ２−アミノキノリン化合物
US7355047B2 (en) * 2002-05-14 2008-04-08 The Regents Of The University Of California Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof
IS7839A (is) * 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
AR042486A1 (es) 2002-12-18 2005-06-22 Glaxo Group Ltd Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
JP2005162726A (ja) * 2003-01-24 2005-06-23 Tanabe Seiyaku Co Ltd ピラゾロピリミジン化合物およびその製法
TW200418835A (en) 2003-01-24 2004-10-01 Tanabe Seiyaku Co A pyrazolopyrimidine compound and a process for preparing the same
US20050031652A1 (en) 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
JP2006514964A (ja) * 2003-03-12 2006-05-18 アボット・ラボラトリーズ 抗菌剤としてのナフチリジン誘導体
DE102004004971B3 (de) * 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel
US7470706B2 (en) 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE102004004972B3 (de) 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Heterocyclisch substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7498341B2 (en) 2004-01-31 2009-03-03 Sanofi Aventis Deutschland Gmbh Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE502005007840D1 (de) * 2004-01-31 2009-09-17 Sanofi Aventis Deutschland 7-phenylamino-4-chinolon-3-carbonsäure-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US7402674B2 (en) 2004-01-31 2008-07-22 Sanofi-Aventis Deutschland Gmbh, 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
WO2006048146A1 (en) 2004-11-01 2006-05-11 F. Hoffmann-La Roche Ag Quinoline as allosteric enhancers of the gaba-b receptors
EP1819342A4 (en) 2004-12-03 2008-12-17 Merck & Co Inc QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS
WO2006128802A2 (en) 2005-06-02 2006-12-07 F. Hoffmann-La Roche Ag 3-methanesulfonylquinolines as gaba-b enhancers
PL1931660T3 (pl) 2005-09-29 2012-12-31 Sanofi Sa Pochodne fenylo-[1,2,4]-oksadiazol-5-onu z grupą fenylową, sposoby ich wytwarzania i ich zastosowanie jako środków farmaceutycznych
TW200824678A (en) 2006-08-11 2008-06-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
JP5373613B2 (ja) 2006-10-16 2013-12-18 バイオノミクス リミテッド 新規な抗不安薬化合物
AR076687A1 (es) 2009-05-18 2011-06-29 Infinity Pharmaceuticals Inc Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen
WO2012109108A1 (en) 2011-02-07 2012-08-16 Biogen Idec Ma Inc. S1p modulating agents
JP2014510065A (ja) 2011-03-02 2014-04-24 バイオノミックス リミテッド 治療薬としての新規な小分子
WO2012116410A1 (en) 2011-03-02 2012-09-07 Bionomics Limited Methods of treating a disease or condition of the central nervous system
CN103649086A (zh) 2011-05-12 2014-03-19 生态学有限公司 制备萘啶的方法

Also Published As

Publication number Publication date
DK2074123T3 (da) 2013-01-14
CA2954376A1 (en) 2008-04-24
US20130012509A1 (en) 2013-01-10
US20150166534A1 (en) 2015-06-18
EP2540722A1 (en) 2013-01-02
JP2013189453A (ja) 2013-09-26
EP2540722B1 (en) 2016-06-08
SI2074123T1 (sl) 2013-03-29
US9975892B2 (en) 2018-05-22
EP2074123B1 (en) 2012-12-05
JP6138191B2 (ja) 2017-05-31
JP5739476B2 (ja) 2015-06-24
JP2010506829A (ja) 2010-03-04
EP2074123A1 (en) 2009-07-01
AU2007312936A1 (en) 2008-04-24
US20170183347A1 (en) 2017-06-29
US20130012508A1 (en) 2013-01-10
US8551990B2 (en) 2013-10-08
JP5373613B2 (ja) 2013-12-18
ES2399071T3 (es) 2013-03-25
US20180105524A1 (en) 2018-04-19
JP2015155444A (ja) 2015-08-27
US8906912B2 (en) 2014-12-09
EP2074123A4 (en) 2011-09-07
JP2017105818A (ja) 2017-06-15
US9573945B2 (en) 2017-02-21
AU2007312936B2 (en) 2013-09-26
US20100105678A1 (en) 2010-04-29
PT2074123E (pt) 2013-01-22
CA2666219A1 (en) 2008-04-24
US20140045839A1 (en) 2014-02-13
WO2008046135A1 (en) 2008-04-24
US8614212B2 (en) 2013-12-24
JP6506322B2 (ja) 2019-04-24
US8293737B2 (en) 2012-10-23
US10233181B2 (en) 2019-03-19
CA2954376C (en) 2019-06-11
HK1132268A1 (en) 2010-02-19
CA2666219C (en) 2017-02-07
NZ576036A (en) 2010-10-29

Similar Documents

Publication Publication Date Title
HK1132268A1 (en) Novel anxiolytic compounds
EP2034838A4 (en) NOVEL CONNECTIONS
EP2032142A4 (en) NOVEL CONNECTIONS
EP1981596A4 (en) NEW CONNECTIONS
GB0603550D0 (en) Novel compounds
EP1981900A4 (en) NEW COMPOUNDS
GB0605462D0 (en) Novel compounds
GB0602900D0 (en) Novel Compounds
EP2031965A4 (en) NEW COMPOUNDS
GB0607840D0 (en) Novel compounds
GB0600483D0 (en) Novel compounds
GB0608452D0 (en) Novel compounds
GB0607892D0 (en) Novel compounds
GB0624901D0 (en) Novel compounds E
GB0608976D0 (en) Novel compounds
GB0601294D0 (en) Novel compounds
GB0602133D0 (en) Novel compounds
GB0602237D0 (en) Novel compounds
GB0602238D0 (en) Novel compounds
GB0608978D0 (en) Novel compounds
GB0601728D0 (en) Novel Compounds
GB0608567D0 (en) Novel compounds
GB0608566D0 (en) Novel compounds
GB0602800D0 (en) Novel Compounds
GB0608457D0 (en) Novel compounds